Prof Charles Mullighan speaks to ecancer about genomic data from the ECOG Akron E 1910 study he presented at ASH 2025.

This study highlights the effectiveness of blinatumomab combined with chemotherapy for adults with acute lymphoblastic leukaemia.

Prof Mullighan explains that the study identifies over 20 subgroups of the disease and explores the relationship between genomic alterations, minimal residual disease response, and treatment outcomes.

He reports that the analysis underscores the significance of tumour genomics in shaping future treatment approaches.